Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Sangamo Therapeutics Inc.

    NASDAQ: SGMO · Real-Time Price · USD
    0.48
    -0.02 (-4.57%)
    At close: Jun 13, 2025, 3:59 PM

    Sangamo Therapeutics Statistics

    Share Statistics

    Sangamo Therapeutics has 245.4M shares outstanding. The number of shares has increased by 8.29% in one year.

    Shares Outstanding

    n/a
    		 245.4M

    Shares Change (YoY)

    n/a
    		 8.29%

    Shares Change (QoQ)

    n/a
    		 7.7%

    Owned by Institutions (%)

    n/a
    		 29.56%

    Shares Floating

    n/a
    		 237.58M

    Failed to Deliver (FTD) Shares

    n/a
    		 72,128

    FTD / Avg. Volume

    n/a
    		 1.02%

    Short Selling Information

    The latest short interest is 31.01M, so 12.64% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 31.01M

    Short % of Shares Out

    n/a
    		 12.64%

    Short % of Float

    n/a
    		 12.77%

    Short Ratio (days to cover)

    n/a
    		 8.82

    Valuation Ratios

    The PE ratio is -2.1 and the forward PE ratio is -1.43. Sangamo Therapeutics's PEG ratio is 0.03.

    PE Ratio

    n/a
    		 -2.1

    Forward PE

    n/a
    		 -1.43

    PS Ratio

    n/a
    		 3.56

    Forward PS

    n/a
    		 0.4

    PB Ratio

    n/a
    		 9.04

    P/FCF Ratio

    n/a
    		 -3.05

    PEG Ratio

    n/a
    		 0.03
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Sangamo Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 1.13, with a Debt / Equity ratio of 1.34.

    Current Ratio

    n/a
    		 1.13

    Quick Ratio

    n/a
    		 1.13

    Debt / Equity

    n/a
    		 1.34

    Debt / EBITDA

    n/a
    		 -0.34

    Debt / FCF

    n/a
    		 -0.45

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $315,846.99

    Profits Per Employee

    n/a
    		 $-535,196.72

    Employee Count

    n/a
    		 183

    Asset Turnover

    n/a
    		 0.57

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -167K

    Effective Tax Rate

    n/a
    		 0.17%

    Stock Price Statistics

    The stock price has increased by -10.17% in the last 52 weeks. The beta is 1.21, so Sangamo Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.21

    52-Week Price Change

    n/a
    		 -10.17%

    50-Day Moving Average

    n/a
    		 0.61

    200-Day Moving Average

    n/a
    		 1.16

    Relative Strength Index (RSI)

    n/a
    		 43.61

    Average Volume (20 Days)

    n/a
    		 7,040,353

    Income Statement

    In the last 12 months, Sangamo Therapeutics had revenue of 57.8M and earned -97.94M in profits. Earnings per share was -0.49.

    Revenue

    n/a
    		 57.8M

    Gross Profit

    n/a
    		 57.8M

    Operating Income

    n/a
    		 -103.97M

    Net Income

    n/a
    		 -97.94M

    EBITDA

    n/a
    		 -89.09M

    EBIT

    n/a
    		 -98.45M

    Earnings Per Share (EPS)

    n/a
    		 -0.49
    Full Income Statement

    Balance Sheet

    The company has 41.92M in cash and 30.57M in debt, giving a net cash position of 11.35M.

    Cash & Cash Equivalents

    n/a
    		 41.92M

    Total Debt

    n/a
    		 30.57M

    Net Cash

    n/a
    		 11.35M

    Retained Earnings

    n/a
    		 -1.5B

    Total Assets

    n/a
    		 86.17M

    Working Capital

    n/a
    		 -11.96M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -67.14M and capital expenditures -267K, giving a free cash flow of -67.41M.

    Operating Cash Flow

    n/a
    		 -67.14M

    Capital Expenditures

    n/a
    		 -267K

    Free Cash Flow

    n/a
    		 -67.41M

    FCF Per Share

    n/a
    		 -0.33
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -179.88% and -169.45%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -179.88%

    Pretax Margin

    n/a
    		 -169.74%

    Profit Margin

    n/a
    		 -169.45%

    EBITDA Margin

    n/a
    		 -154.13%

    EBIT Margin

    n/a
    		 -179.88%

    FCF Margin

    n/a
    		 -116.62%

    Dividends & Yields

    SGMO does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for SGMO is $3, which is 500% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $3

    Price Target Difference

    n/a
    		 500%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -26.62

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist